Genmab A/S Sponsored ADR

GMAB Healthcare Biotechnology

Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.

Revenue
+24.9%
EPS
−9.26%
Free cash flow
−7.69%

Quarter to June 2026, against a year earlier

53.91 1.17 +2.22%
Market cap
$31.5B
P/E
41.7×
Fwd P/E
47.3×
Dividend yield
—
F-score
4/9
Altman Z
2.78
Beneish M
−3.00
Dividend safety
n/a

Genmab A/S Sponsored ADR (GMAB) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, Genmab A/S Sponsored ADR (GMAB) trades at a P/E ratio of 41.7×. Over the past ten years it has ranged from 2.1× (October 2018) to 78.6× (September 2021); the current reading is higher than 88% of that period. That is above the Biotechnology industry median of 10.3× and above the Healthcare sector median of 25.2×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 19.9× 68.53%
FY2024 11.8× (64.38%)
FY2023 33.1× (9.22%)
FY2022 36.5× (31.79%)
FY2021 53.5× 44.63%
FY2020 37.0× 10.20%
FY2019 33.5× 333.68%
FY2018 7.7× 158.55%
FY2017 3.0× (51.07%)
FY2016 6.1× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 21.6× 6.42%
Mar 2026 20.3× 2.29%
Dec 2025 19.9× 52.90%
Sep 2025 13.0× 25.81%
27 more quarters

Against its own ten years

Low 2.1× High 78.6×
Ten-year median 22.2×
Current reading's percentile 88

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on GMAB